Valeant Pharmaceuticals International VRX
Citron's 'next Enron' attack on Valeant is a 1963 AmEx Salad Oil rerun — Philidor is ~7% of sales, the franchise is intact, and VRX at 7x cash EPS offers 60-215% upside.
Thesis
Pershing Square's third Valeant deck defends the position after Citron Research's October 21, 2015 report branded VRX the 'next Enron' and the stock crashed from roughly $260 to $111.50 in six weeks. Ackman argues Citron's channel-stuffing claim is verifiably false: Valeant's accounting for sales through Philidor — its largest specialty pharmacy at just 5.9% of YTD revenue — is more conservative than for traditional distributors. Valeant's under-investment in disclosure, PR and IR made it susceptible to attack, but the underlying franchise is intact — Bausch & Lomb, Salix gastrointestinal, emerging markets and US dermatology delivered 13-15% organic growth. At $111.50 VRX trades at ~7x 2016 cash EPS; a conservative no-M&A model yields $180-$240 per share and a base case $262-$350 (62-215% upside). The closing frame is the 1963 American Express Salad Oil Scandal — panic over a peripheral issue masking a healthy franchise, which the young Buffett bought at the bottom.
SCQA
Valeant is a $40bn specialty pharma leader in dermatology, ophthalmology (Bausch & Lomb), gastroenterology (Salix) and emerging markets, backed by sophisticated long-term holders including Pershing, Ruane Cunniff, T Rowe Price and ValueAct.
Citron's October 21 'next Enron' report triggered a crash from $260 to $111.50; PBMs terminated Philidor; Valeant's opaque disclosure of the $100mm Philidor purchase option and specialty-pharmacy channel left it unable to rebut the channel-stuffing narrative in real time.
Hold and add — Citron's accounting claim is factually wrong, Philidor is only 5.9% of revenue and conservatively consolidated; expect Valeant to terminate Philidor, develop new channel partners, and the ad hoc board committee to confirm compliance.
Conservative no-acquisition model yields $180-$240 per share; base case with 7.5% organic EBITDA CAGR and $10bn/year of M&A yields $262-$350 — 62% to 215% upside from $111.50 as Philidor noise clears and the franchise reasserts itself.
The three reasons
- 1
Citron's 'next Enron' channel-stuffing claim is verifiably false; Philidor accounting is more conservative than traditional distributor treatment
- 2
Philidor is only 5.9% of YTD sales; core franchises grew 13-15% organically in 2015
- 3
Like AmEx after the 1963 Salad Oil Scandal, the franchise is resilient and the dislocation is a Buffett-style buying opportunity
Primary demands
- Hold and add to VRX into the Citron-induced dislocation
- Valeant should terminate the Philidor relationship and develop new specialty-pharmacy channel partners
- Valeant must materially increase transparency and invest in PR, government and investor relations
- Ad hoc board committee should complete the Philidor compliance review and publish findings
KPIs cited
Pattern membership
Precedents cited
- American Express Salad Oil Scandal (1963) — Buffett buying AmEx at the panic low
- Novartis specialty-pharmacy kickback case (2011-2015, $390mm DOJ settlement)
Slide gallery ·
Notes
Rare specimen: an activist publicly defending an existing long position mid-crisis against a short-seller attack, rather than mounting a new campaign. Posture is activist_defense + undervaluation, not initial_thesis — this is Pershing's THIRD Valeant presentation, delivered at the peak of the Philidor scandal nine days after Citron's 'next Enron' report (Oct 21, 2015) and one day after CVS Caremark, Express Scripts and OptumRx terminated Philidor. Key rhetorical moves: (a) contradicting R&O/Reitz's own emails against their lawsuit claims (pp. 15-16) — classic 'their own words' refutation; (b) surfacing Valeant management's incomplete answers to three specific questions (p. 26), hedging the defense; (c) color-coded timelines of Philidor/R&O corporate events (pp. 13-14, 17) to dismantle the channel-stuffing narrative chronologically; (d) conceding Valeant's failings (opacity, under-invested PR/IR, 'very costly mistake') to buy credibility before defending the franchise; (e) AmEx Salad Oil 1963 analogy (pp. 35-36) as closing frame, implicitly casting Ackman as the young Buffett buying the panic low. Stake not disclosed as a percentage in this document, but 16.5mm shares at $196 (Feb-Mar 2015), 3mm at $199 (Mar 16, 2015) and 2mm at ~$108 (Oct 21, 2015) are referenced. Cover names only 'Pershing Square Capital Management, L.P.' with no named author, hence author_name is null.